Current Report Filing (8-k)
March 04 2016 - 3:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
_______________________
Date of Report: February 29, 2016 (Date of earliest event reported)
|
CAPSTONE THERAPEUTICS CORP. |
|
|
(Exact name of registrant as specified in its charter) |
|
Delaware |
|
000-21214 |
|
86-0585310 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
1275 West Washington Street, Suite 104, Tempe, Arizona |
|
85281 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
(602) 286-5520
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
[ ] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Page 2 of 4
Section 4 – Matters Related to Accountants and Financial
Statements
Item 4.01 Changes in Registrant’s Certifying Accountant
(a) Resignation of Previous Independent Registered Public Accounting Firm
The Company notified the Company’s independent registered public accounting firm, Moss Adams LLP (“MA”),
that to preserve cash for operations, it could not authorize MA to commence the audit of its financial statements to be included
in its Annual Report on Form 10-K for the year ended December 31, 2015. On February 29, 2016, MA notified the Company of its decision
to resign. The decision not to authorize MA to commence the audit was initiated and approved by the Company’s Board of Directors.
MA’s audit reports on the Company’s financial statements for the
two most recent fiscal years ended December 31, 2014 and 2013, did not contain an adverse opinion or a disclaimer of opinion,
but for the most recent year, the MA audit report was qualified as to uncertainty with regards to the Company’s ability
to raise funding to implement the future business strategy of the Company, which raised substantial doubt about the
Company’s ability to continue as a going concern. The prior year’s audit report was not qualified or modified as
to uncertainty, audit scope or accounting principles. During the Company’s two most recent fiscal years and in the
subsequent interim period from January 1, 2016 through March 4, 2016, there were (i) no disagreements between the Company and
MA on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of MA, would have caused MA to make reference to the subject matter of the
disagreement in their reports on the financial statements for such years, and (ii) no “reportable events” as that
term is defined in Item 304(a)(1)(v) of Regulation S-K. The Company has provided MA with a copy of this disclosure and has
requested that MA furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not MA
agrees with the above statements. A copy of such letter dated March 4, 2016 from MA is filed as Exhibit 16.1 to this Form
8-K.
Section 9 – Financial Statements and
Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) |
|
Exhibits |
|
|
|
Exhibit No. |
|
Description |
|
|
|
16.1 |
|
Letter from Moss Adams LLP to the Securities and Exchange Commission dated March 4, 2016. |
Page 3 of 4
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 4, 2016 |
CAPSTONE THERAPEUTICS CORP. |
|
|
|
|
|
|
|
/s/ John M. Holliman, III |
|
|
John M. Holliman, III |
|
|
Executive Chairman and CEO |
Page 4 of 4
Exhibit Index
Exhibit No. |
|
Description |
|
|
|
16.1 |
|
Letter from Moss Adams LLP to the Securities and Exchange Commission dated March 4, 2016. |
Exhibit 16.1
March 4, 2016
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6561
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated February 29, 2016 of Capstone Therapeutics Corp.
(the “Company”) and are in agreement with the statements contained therein, except that we are not in a position to
agree or disagree with the Company’s statement in paragraph 1 that the Company’s Board of Directors initiated and approved
the decision to not authorize us to commence the audit of the Company’s 2015 consolidated financial statements.
Respectfully,
/s/ Moss Adams LLP
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jul 2023 to Jul 2024